Robison Nathan J, Kieran Mark W
Pediatric Neuro-Oncology Program, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, 4650 W Sunset Blvd, MS#54, Los Angeles, CA, 90027, USA,
J Neurooncol. 2014 Aug;119(1):7-15. doi: 10.1007/s11060-014-1448-8. Epub 2014 May 3.
Diffuse intrinsic pontine glioma (DIPG) is a disease of childhood whose abysmal prognosis has remained unchanged for over 50 years. Biologic investigation has been stymied by lack of pretreatment tissue, as biopsy has been reserved for atypical cases. Recent advances in surgical and molecular-analytic techniques have increased the safety and potential utility of biopsy; brainstem biopsy has now been incorporated into several prospective clinical trials. These and other recent efforts have yielded new insights into DIPG molecular pathogenesis, and opened new avenues for investigation.
弥漫性脑桥内生型胶质瘤(DIPG)是一种儿童疾病,其极差的预后在50多年来一直没有改变。由于活检仅用于非典型病例,缺乏治疗前组织使得生物学研究受到阻碍。手术和分子分析技术的最新进展提高了活检的安全性和潜在效用;脑干活检现已纳入多项前瞻性临床试验。这些以及最近的其他努力为DIPG分子发病机制带来了新的见解,并开辟了新的研究途径。